Pfizer Provides Update on U.S. FDA Review of Abrocitinib and XELJANZ® Filings
Retrieved on:
Wednesday, July 21, 2021
Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, Health care, Life sciences, Immunosuppressants, Tofacitinib, Pfizer, Health, Clinical trials, Food and Drug Administration, Abrocitinib, XELJANZ® (tofacitinib), the ORAL Surveillance Study, Pfizer: Breakthroughs That Change Patients’ Lives, ABROCITINIB, XELJANZ® (TOFACITINIB), THE ORAL SURVEILLANCE STUDY, PFIZER: BREAKTHROUGHS THAT CHANGE PATIENTS’ LIVES
Pfizer is continuing to work with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to review the full results and analysis.
Key Points:
- Pfizer is continuing to work with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to review the full results and analysis.
- Patients treated with XELJANZ* are at increased risk for developing serious infections that may lead to hospitalization or death.
- * Unless otherwise stated, XELJANZ in the Important Safety Information refers to XELJANZ, XELJANZ XR, and XELJANZ Oral Solution.
- Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.